From today's Wall Street Journal (subscription may be required) Over the next few years, the pharmaceutical business will hit a wall. Some of the top-selling drugs in industry history will become …
Pharma News 11_9
A huge week for news, especially on the cardiovascular front: Prasugrel, the Lilly/Daiichi-Sankyo blood thinner, was the biggest headline grabber. This potential blockbuster came in with mixed …
Pharma News 9_14
Prasugrel, the upcoming rival to $6 billion drug Plavix, gets a write-up. This is a crucial new drug for co-promote partners Daiichi-Sankyo and Eli Lilly. Good Samaritan drug rep loses leg, gains …
Pharma News 8_24
Novartis gets approval for Reclast, a once-per-year osteoporosis treatment. That's a game-changer - very cool advance that should lead to far better patient compliance. A long-ish article on Wyeth's …
Pharma News 8_3
A minor comeback for Novartis' Zelnorm. Avandia gets a reprieve, of sorts...to remain on the market, but undoubtedly with a raft of warnings and cautions. Meanwhile, more encouraging data on Actos, …
Pharma News 7_27
Two weeks worth of news articles linked here: Medical News Actos: safer than Avandia? Cialis going toward a once-daily version (but shouldn't it be once every day-and-a-half??) Novartis gets some …